For years, the biggest complaint about GLP-1 drugs has been simple: nobody likes needles. Orforglipron is Eli Lilly's answer to that — a once-daily pill that works through the same core mechanism as semaglutide (Ozempic, Wegovy), but you just swallow it with a glass of water. No injections, no refrigeration, no food restrictions. If it clears the FDA, it'll be the first oral GLP-1 approved specifically for weight loss in the US.
This page covers what we know about orforglipron based on the Phase 3 trial data and Lilly's FDA filing. It will be updated after the FDA issues its decision, currently expected around April 10, 2026.
Important: This page is for informational purposes only and is not medical advice. Always follow your prescriber's instructions.
Orforglipron is a GLP-1 receptor agonist — the same basic mechanism as semaglutide. It binds to GLP-1 receptors in your brain and gut, suppressing appetite, slowing digestion, and helping regulate blood sugar. If you're familiar with how Wegovy or Ozempic works, you already understand most of what orforglipron does.
The key difference is how it's made. Semaglutide and tirzepatide are peptides — large, complex molecules that have to be injected because stomach acid would destroy them before they could be absorbed. Orforglipron is a small molecule, which means it's more like a traditional drug in pill form. Your gut can absorb it intact.
A few practical advantages that come from this:
What it is not: a dual agonist. Tirzepatide hits both GLP-1 and GIP receptors, which is why it tends to produce stronger weight loss results. Orforglipron is GLP-1 only, so it's more comparable to semaglutide than to tirzepatide in terms of mechanism.
Based on the Phase 3 trials, orforglipron uses a gradual titration starting at 1 mg and working up over several months. The final FDA-approved label may differ slightly, but this is what the trials used:
| Weeks | Daily Dose | Notes |
|---|---|---|
| 1–4 | 1 mg | Starting dose |
| 5–8 | 3 mg | |
| 9–12 | 6 mg | Lowest maintenance dose tested |
| 13–16 | 12 mg | Mid-range maintenance dose |
| 17–20 | 24 mg | Titration step (not a primary maintenance) |
| 21+ | 36 mg | Maximum dose tested; best efficacy |
A few things worth noting:
This is the honest answer most people want: orforglipron is less effective for weight loss than the leading injectables, but it closes the gap meaningfully — and it's a pill.
| Metric | Orforglipron 36 mg | Semaglutide 2.4 mg (Wegovy) | Tirzepatide 15 mg (Zepbound) |
|---|---|---|---|
| Route | Daily pill | Weekly injection | Weekly injection |
| Weight loss (trial avg.) | ~11–12% body weight | ~15% body weight | ~20% body weight |
| Duration | 72 weeks | 68 weeks | 72 weeks |
| Mechanism | GLP-1 only | GLP-1 only | GLP-1 + GIP dual agonist |
| Nausea rate | 13–16% | ~44% | ~18–33% |
| Discontinuation (side effects) | 5–10% | ~5–7% | ~4–7% |
What this means practically:
One surprisingly interesting data point: The ATTAIN-MAINTAIN trial specifically looked at people who switched from injectable GLP-1s to orforglipron. People who switched from Wegovy maintained about 95% of their prior weight loss. People who switched from Zepbound maintained about 80%. So if you're stabilized on an injectable and switch to the pill, you're likely to hold most of your progress — you're not starting from scratch.
The same general GI side effects you'd expect from any GLP-1: nausea, diarrhea, constipation, indigestion. The profile is similar to other GLP-1s, with a few differences worth knowing:
Lilly submitted orforglipron to the FDA under Priority Review, which means the agency committed to a faster-than-standard review timeline. The PDUFA date (the FDA's target decision date) is April 10, 2026.
No Advisory Committee meeting was scheduled, which is generally read as a positive sign — the FDA typically convenes an AdCom when there are significant questions about safety or efficacy that benefit from outside expert input. Not needing one suggests the data came in clean.
Approval isn't guaranteed, but the probability is estimated high (around 84%) based on the strength of the trial data and Lilly's track record with the FDA.
On pricing (if approved):
Lilly has been fairly transparent about their intended pricing through LillyDirect, their direct-to-patient platform:
That $399 list price for the max dose is competitive with Wegovy and Zepbound, which run $1,000+ per month at list price before insurance or GoodRx-type discounts.
On supply: One of the bigger logistical stories here is that Lilly has reportedly stockpiled $1.5 billion of orforglipron inventory ahead of the launch. The GLP-1 shortages that plagued semaglutide and tirzepatide in 2023–2024 were a massive headache for patients and a PR problem for the whole category. Lilly is clearly trying to avoid a repeat.
This is the practical question for a lot of people on this site.
First: orforglipron is almost certainly not compoundable. It's a patented small molecule, not a peptide. Compounding pharmacies have made compounded semaglutide and tirzepatide available partly because the FDA's shortage list created a legal pathway. Orforglipron isn't on any shortage list (it hasn't even launched), it's not a peptide, and Lilly has clearly planned for adequate supply. There is no realistic compounding pathway here.
Second: it's not a replacement for compounded tirzepatide. If you're getting 15–20% weight loss on tirzepatide, switching to orforglipron would likely mean accepting meaningfully less weight loss (11–12%). Plus you lose the GIP agonist effect. If tirzepatide is working well for you, this isn't an upgrade or even a lateral move.
Where orforglipron could make sense:
On cost vs. compounded: Compounded semaglutide and tirzepatide are typically $100–$200/month from telehealth providers, often less. Orforglipron at $149–$399/month list price is more expensive than most compounded options — but it may be more accessible than branded injectables for people without insurance coverage.
If you want to compare your current semaglutide dosing to what orforglipron might mean for you, the Semaglutide Calculator can help you think through your current protocol. For tirzepatide context, the Tirzepatide Dose Calculator is the place to start.
This page was last updated March 2026 and will be updated after the FDA issues its decision. Information is based on published Phase 3 trial data and publicly available FDA filing information. Nothing here is medical advice — talk to your prescriber about what's right for you.